Hikma Pharmaceuticals (CHIX:HIKL) Change In Payables And Accrued Expense : £0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Change In Payables And Accrued Expense?

Hikma Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was £0 Mil. It means Hikma Pharmaceuticals's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Hikma Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was £0 Mil. It means Hikma Pharmaceuticals's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Hikma Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Hikma Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Change In Payables And Accrued Expense Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Hikma Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0 Mil.

Hikma Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (CHIX:HIKl) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines